Pharmaceutical CDMO for Formulations Market - Databook 2025 to 2034

The global pharmaceutical CDMO for formulations market size was estimated at USD 45.43 billion in 2024 and is projected to be worth around USD 96.57 billion by 2034, growing at a CAGR of 7.83% from 2025 to 2034.

Highlights of the Pharmaceutical CDMO for Formulations Market

• North America dominated the global pharmaceutical CDMO for formulations market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By dosage form, the oral solids segment holds a dominant presence in the market in 2024.
• By dosage form, the injectables segment is expected to grow at the fastest rate in the market during the forecast period.
• By therapeutic area, the oncology segment holds a dominant presence in the pharmaceutical CDMO for formulations market in 2024.
• By therapeutic area, the infectious diseases segment is expected to grow at the fastest rate in the market during the forecast period.
• By end user, the pharmaceutical companies segment holds a dominant presence in the market in 2024.
• By end user, the biopharmaceutical companies segment is expected to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

The pharmaceutical Contract Development and Manufacturing Organization market for formulations is a remarkable part of the broader CDMO field, aiming to outsource the advancement and production of drug formulations. This market is boosted by growing outsourcing trends in the pharmaceutical domain, the demand for specialized capabilities, and the cost-efficacy of CDMOs. Many CDMOs have access to customized equipment and expertise that is not accessible in-house for many pharmaceutical firms. Pharmaceutical firms are stretching into new markets, and CDMOs assist them in navigating regulatory and logistical challenges.

Pharmaceutical CDMO for Formulations Market: Stats and Figures

• In February 2023, WuXi XDC and Cidara Therapeutics, Inc. disclosed an expansion of their existing working relationship under which WuXi XDC will offer investigational new drug (IND)-permitting chemistry, controls, and manufacturing (CMC) advancement services for Cidara’s CD73 oncology DFC program.

Industry Leader Announcements

• Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis

“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,” said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. “We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”

• Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher

“Continuing our strong track record of high-impact innovation, the Orbitrap Astral Zoom and Orbitrap Excedion Pro represent a significant leap forward in mass spectrometry, enabling researchers around the world to accelerate discovery and advance the pace of transformative scientific breakthroughs,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “With one of the industry’s broadest portfolios for omics and proteomics research from reagents and consumables to spatial imaging systems and our state-of-the-art mass spec workflows our solutions allow researchers to quantify and validate proteins with greater precision and scale than ever before.”

How AI Has Benefitted the Pharmaceutical CDMO for Formulations Market

AI has transformed the pharmaceutical CDMO field for formulations by speeding up drug discovery, optimizing production processes, and enhancing quality control. AI can optimize trial design, enhance patient recruitment, and handle patient responses in real time, contributing to faster and more efficient clinical trials. AI can optimize resource allocation, lessen waste, and ensure efficient production planning. AI can automate information collection and reporting, guaranteeing compliance with regulatory standards and decreasing the risk of regulatory penalties.

Recent Developments in the Pharmaceutical CDMO for Formulations Market

• In April 2025, AustinPx disclosed the introduction of the KinetiLease program, permitting pharmaceutical firms to lease the firm’s KinetiSol research-scale equipment. This program permits firms to implement this powerful amorphous dispersion production tool into their own R&D labs.

Geographical Insights

The pharmaceutical CDMO for formulations market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. The Asia Pacific region is projected to be the fastest-growing in the market during the forecast period.

North America

North America dominated the global pharmaceutical CDMO for formulations market in 2024. North America is the center of many of the world's contributing pharmaceutical firms, which creates a high need for CDMO services. Strong intellectual property protection and regulatory environments affect investment and collaboration within the CDMO field. Significant investment in biopharmaceuticals, including gene and cellular therapies, requires specialized CDMO capabilities.

Europe

Europe is experiencing rapid growth in the pharmaceutical CDMO for formulations market during the forecast period. Pharmaceutical firms are increasingly outsourcing advancement and manufacturing processes to CDMOs. An increasing number of pharmaceutical activities, including new drug development and clinical trials, drive up the requirement for CDMO services.

Asia Pacific

Asia Pacific is projected to be the fastest-growing in pharmaceutical CDMO formulations during the forecast period. Asia-Pacific provides cost-effective production, which is a major draw for pharmaceutical firms seeking CDMO partners. Pharmaceutical firms are progressively outsourcing their drug development and production processes to CDMOs, mainly in Asia-Pacific, to reduce expenses and enhance efficiency.

Competitive Landscape

The global pharmaceutical CDMO market is greatly competitive, with a mix of large, well-known players and smaller, specialized firms. Key strategies employed by CDMOs include amplifying capabilities in complex formulations and biologics, leveraging developed technologies to enhance efficiency, and focusing on customer-centric solutions and quality assurance.

• Company Name: WuXi AppTec, Inc.
• Year of Incorporation: 2000
• Headquarters: Shanghai, China

WuXi AppTec functions in the highly competitive CRDMO (Contract Research, Development, and Manufacturing Organization) market, facing competition from both well-known players and emerging firms.

• Company Name: Piramal Pharma Solutions
• Year of Incorporation: 2020
• Headquarters: Mumbai

Piramal Pharma Solutions functions in the highly competitive pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector, facing difficulties in a market with diverse major players. Their valuation adjustments feature their unique position within the domain, driven by factors such as a high price-to-earnings ratio and a very low return on equity.

• Company Name: Nipro Corporation
• Year of Incorporation: 1954
• Headquarters: Osaka, Osaka, Japan

Nipro's competitive strategy includes targeting, providing products to end-users, cooperating with academic institutions, and facilitating joint ventures.